Back to Search
Start Over
Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p869-869, 1p
- Publication Year :
- 2023
-
Abstract
- *Drs. Yifan Zhai and Xiaojun Huang are co-corresponding authors.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64589240
- Full Text :
- https://doi.org/10.1182/blood-2023-187740